We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

63 hedge funds and large institutions have $168M invested in Cue Biopharma in 2019 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 6

227% more capital invested

Capital invested by funds: $51.3M → $168M (+$116M)

144% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 9

40% more funds holding

Funds holding: 45 → 63 (+18)

0.63% more ownership

Funds ownership: 0.9% → 1.53% (+0.63%)

Holders
63
Holders Change
+18
Holders Change %
+40%
% of All Funds
1.24%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
24
Increased
22
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$19.6M
2
MP
Mangrove Partners
Connecticut
+$6.3M
3
CAG
Crestwood Advisors Group
Massachusetts
+$2.83M
4
PM
Precept Management
Texas
+$1.78M
5
BlackRock
BlackRock
New York
+$1.74M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$422K
2
HSBC Holdings
HSBC Holdings
United Kingdom
-$397K
3
Millennium Management
Millennium Management
New York
-$117K
4
Citigroup
Citigroup
New York
-$108K
5
PGM
Parian Global Management
New York
-$93K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$29.7M +$19.6M +62,333 New
NCM
2
Nantahala Capital Management
Connecticut
$22.3M +$280K +891 +2%
BlackRock
3
BlackRock
New York
$22M +$1.74M +5,547 +14%
SPC
4
Slate Path Capital
New York
$14.1M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$14.1M +$1.41M +4,485 +18%
MP
6
Mangrove Partners
Connecticut
$9.55M +$6.3M +20,047 New
State Street
7
State Street
Massachusetts
$5.3M +$500K +1,592 +17%
6CM
8
683 Capital Management
New York
$5.08M +$210K +667 +7%
CA
9
Corriente Advisors
Texas
$4.52M +$2.98M +9,500 New
CAG
10
Crestwood Advisors Group
Massachusetts
$4.29M +$2.83M +9,000 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$4.18M +$550K +1,750 +25%
Northern Trust
12
Northern Trust
Illinois
$3.49M -$37.4K -119 -2%
PM
13
Precept Management
Texas
$2.7M +$1.78M +5,667 New
BL
14
Bleichroeder LP
New York
$2.62M +$1.73M +5,500 New
PM
15
Prosight Management
Texas
$2.19M +$1.44M +4,588 New
N
16
Nuveen
North Carolina
$2.08M +$637K +2,027 +87%
Schroder Investment Management Group
17
Schroder Investment Management Group
United Kingdom
$1.47M +$971K +3,091 New
VC
18
Voss Capital
Texas
$1.47M +$968K +3,083 New
Morgan Stanley
19
Morgan Stanley
New York
$1.21M +$497K +1,583 +166%
SMH
20
Sanders Morris Harris
Texas
$1.14M +$730K +2,325 New
Bank of New York Mellon
21
Bank of New York Mellon
New York
$1.05M +$106K +339 +18%
SPC
22
Sigma Planning Corp
Michigan
$1.04M +$54K +172 +9%
Invesco
23
Invesco
Georgia
$937K +$618K +1,966 New
UBS Group
24
UBS Group
Switzerland
$933K +$108K +344 +21%
Stifel Financial
25
Stifel Financial
Missouri
$887K – – –
1
2 3

CUE Hedge Fund Activity: Q4 2019 in Review

63 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q4 2019, worth a combined $168M — up 227% from $51.3M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CUE positions and 6 closed out — a net gain of 18 holders — while 22 added to existing stakes and 9 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $19.6M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $422K sold.

  • 63 institutional investors held Cue Biopharma (CUE) as of Q4 2019, up from 45 in Q3 2019.
  • Funds reported $168M of Cue Biopharma stock for Q4 2019, up 227% quarter-over-quarter.
  • 24 funds opened new Cue Biopharma positions in Q4 2019 and 6 closed out, a net change of +18 holders.
  • The largest Cue Biopharma buyer in Q4 2019 was Avoro Capital Advisors, an estimated $19.6M added.
  • The largest Cue Biopharma seller in Q4 2019 was Sphera Funds Management, an estimated $422K sold.

Based on aggregated 13F filings for Q4 2019.